Literature DB >> 16109920

Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension.

Sandra L Merklinger1, Roger A Wagner, Edda Spiekerkoetter, Aleksander Hinek, Russell H Knutsen, M Golam Kabir, Kavin Desai, Shelby Hacker, Lingli Wang, Gordon M Cann, Noona S Ambartsumian, Eugene Lukanidin, Daniel Bernstein, Mansoor Husain, Robert P Mecham, Barry Starcher, Hiromi Yanagisawa, Marlene Rabinovitch.   

Abstract

Transgenic mice overexpressing the calcium binding protein, S100A4/Mts1, occasionally develop severe pulmonary vascular obstructive disease. To understand what underlies this propensity, we compared the pulmonary vascular hemodynamic and structural features of S100A4/Mts1 with control C57Bl/6 mice at baseline, following a 2-week exposure to chronic hypoxia, and after 1 and 3 months "recovery" in room air. S100A4/Mts1 mice had greater right ventricular systolic pressure and right ventricular hypertrophy at baseline, which increased further with chronic hypoxia and was sustained after 3 months "recovery" in room air. These findings correlated with a heightened response to acute hypoxia and failure to vasodilate with nitric oxide or oxygen. S100A4/Mts1 mice, when compared with C57Bl/6 mice, also had impaired cardiac function judged by reduced ventricular elastance and decreased cardiac output. Despite higher right ventricular systolic pressures with chronic hypoxia, S100A4/Mts1 mice did not develop more severe PVD, but in contrast to C57Bl/6 mice, these features did not regress on return to room air. Microarray analysis of lung tissue identified a number of genes differentially upregulated in S100A4/Mts1 versus control mice. One of these, fibulin-5, is a matrix component necessary for normal elastin fiber assembly. Fibulin-5 was localized to pulmonary arteries and associated with thickened elastic laminae. This feature could underlie attenuation of pulmonary vascular changes in response to elevated pressure, as well as impaired reversibility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109920     DOI: 10.1161/01.RES.0000182425.49768.8a

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  43 in total

1.  Effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in proximal and distal pulmonary arterial structure and function.

Authors:  Rebecca R Vanderpool; Ah Ram Kim; Robert Molthen; Naomi C Chesler
Journal:  J Appl Physiol (1985)       Date:  2010-11-18

2.  Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner.

Authors:  Allan Lawrie; Abdul G Hameed; Janet Chamberlain; Nadine Arnold; Aneurin Kennerley; Kay Hopkinson; Josephine Pickworth; David G Kiely; David C Crossman; Sheila E Francis
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

3.  Co-expression of fibulin-5 and VEGF165 increases long-term patency of synthetic vascular grafts seeded with autologous endothelial cells.

Authors:  M Preis; J Schneiderman; B Koren; Y Ben-Yosef; D Levin-Ashkenazi; S Shapiro; T Cohen; M Blich; M Israeli-Amit; Y Sarnatzki; D Gershtein; R Shofti; B S Lewis; Y Shaul; M Y Flugelman
Journal:  Gene Ther       Date:  2015-12-24       Impact factor: 5.250

4.  Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit.

Authors:  Thomas Bertero; Katherine A Cottrill; Yu Lu; Christina M Haeger; Paul Dieffenbach; Sofia Annis; Andrew Hale; Balkrishen Bhat; Vivek Kaimal; Ying-Yi Zhang; Brian B Graham; Rahul Kumar; Rajan Saggar; Rajeev Saggar; W Dean Wallace; David J Ross; Stephen M Black; Sohrab Fratz; Jeffrey R Fineman; Sara O Vargas; Kathleen J Haley; Aaron B Waxman; B Nelson Chau; Laura E Fredenburgh; Stephen Y Chan
Journal:  Cell Rep       Date:  2015-10-22       Impact factor: 9.423

5.  Nuclear factor-kappaB activation in neonatal mouse lung protects against lipopolysaccharide-induced inflammation.

Authors:  Cristina M Alvira; Aida Abate; Guang Yang; Phyllis A Dennery; Marlene Rabinovitch
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

6.  Interleukin-6 overexpression induces pulmonary hypertension.

Authors:  M Kathryn Steiner; Olga L Syrkina; Narasaish Kolliputi; Eugene J Mark; Charles A Hales; Aaron B Waxman
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

7.  Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia.

Authors:  Edward C Dempsey; Marilee J Wick; Vijaya Karoor; Erica J Barr; Dustin W Tallman; Carol A Wehling; Sandra J Walchak; Sven Laudi; Mysan Le; Masahiko Oka; Susan Majka; Carlyne D Cool; Karen A Fagan; Dwight J Klemm; Louis B Hersh; Norma P Gerard; Craig Gerard; York E Miller
Journal:  Am J Pathol       Date:  2009-03       Impact factor: 4.307

8.  Implication of in vivo circulating fibrocytes ablation in experimental pulmonary hypertension murine model.

Authors:  Vandana S Nikam; Sandeep Nikam; Akyl Sydykov; Katrin Ahlbrecht; Rory E Morty; Werner Seeger; Robert Voswinckel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

Review 9.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

10.  Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Robert S Brown; James F Trotter; Inga Peter; Hocine Tighiouart; James A Knowles; Daniel Rabinowitz; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.